jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Indian Journal of Pharmaceutical Education and ResearchNOW IN
Review

Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodelivery

Afzal Haq Asif1, Anroop Nair2, Bandar Aldhubiab2, Sreeharsha Nagaraja2,3★, Girish Meravanige4, Syed Mohammed Basheeruddin Asdaq5, Md. Khalid Anwer6, Arshia Shariff3, Syed Dawood Noor7★ Corresponding author

  1. 1Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.
  2. 2Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, KSA.
  3. 3Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore, Karnataka, INDIA.
  4. 4Department of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa, SAUDI ARABIA.
  5. 5Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh, SAUDI ARABIA.
  6. 6Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Alkharj, SAUDI ARABIA.
  7. 7Department of Pharmacognosy, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore, Karnataka, INDIA.

CORRESPONDENCE

Sreeharsha Nagaraja

Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, KSA.

sharsha@kfu.edu.sa

Received: 11-02-2022; Revised: 21-04-2022; Accepted: 12-05-2022.

Volume 56, Issue 3 · pp. 636–645 · PUBLISHED 2022 · DOI: 10.5530/ijper.56.3.112

View on IJPER original site ↗

ABSTRACT

The characteristic feature of Interstitial cystitis (IC) or bladder pain syndrome is augmented, pressure, or inconvenience in the suprapubic or bladder region. The causative factors for IC are not completely understood however certain underlying disease condition may trigger the pain. The therapy is aimed to provide symptomatic relief, and therefore, the treatment protocols have been established based on experience. Intravesical delivery of drugs has been well explored and found to be most effective in minimizing the symptoms of IC without systemic adverse events. However, the efficacy of drug absorption is limited by the bladder wall permeability and poor absorption of the instilled drugs. The intravesical approach should be coupled with novel nanocarriers such as nanoparticles or liposomes to overcome these limitations. Nanoparticles can easily cross the bladder permeability barrier and enhance the drug retention time in the bladder, making the delivery efficient and promising. This review addresses the current IC management strategies, new potential therapeutic agents of natural origin, and various drugs undergoing clinical trials by different routes of administration.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Asif, A. H., Nair, A., Aldhubiab, B., Nagaraja, S., Meravanige, G., Asdaq, S. M. B., Anwer, M. K., Shariff, A., & Noor, S. D. (2022). Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodelivery. Indian Journal of Pharmaceutical Education and Research, 56(3), 636–645. https://doi.org/10.5530/ijper.56.3.112